North America Hepatitis B Market Report and Forecast 2025-2034
Description
The global hepatitis B market was valued at USD 4.63 Billion in 2024, with North America holding a significant market share. The market is driven by the rising development of innovative therapies. It is expected to grow at a CAGR of 3.37% during the forecast period of 2025-2034, with the values likely to attain USD 6.45 Billion by 2034.
North America Hepatitis B Market Analysis
Hepatitis B is a vaccine-preventable liver infection that can result in a chronic infection leading to cirrhosis, liver cancer, and death. It is caused by the hepatitis B virus (HBV) and affects around 1.6 million people in the United States. The prevalence rate of the infection is higher in black, Hispanic, and Asian populations as compared to whites. Hepatitis B viral infection has the potential to progress to a chronic state and thus is a significant health challenge. Intensive research efforts are accelerating the development of innovative antiviral therapies and immune modulators, which is impacting the global hepatitis B market dynamics. Further, advancements in diagnostic technologies and improvements in healthcare infrastructure are some of the factors that contribute to the North America hepatitis B market growth.
The market is influenced by the presence of a supportive regulatory environment that expedites the introduction of novel treatment options. In February 2024, the global biopharma company GSK plc announced that its investigational antisense oligonucleotide (ASO) bepirovirsen has received Fast Track Designation from the US Food and Drug Administration to treat chronic hepatitis B. Developed jointly with California-based biotechnology company Ionis Pharmaceuticals, the designation request was made based on the positive results from phase IIb trials B-Clear and B-Sure. The company claims that Bepirovirsen (in combination with oral nucleoside/nucleotide analogues) is the only single agent in phase III development that demonstrated a clinically meaningful functional cure response in chronic hepatitis B patients. Such substantial investment in clinical studies by the leading pharmaceutical companies to develop effective medications for this viral infection is poised to boost the North America hepatitis B market demand in the forecast period.
Increased awareness initiatives and education campaigns regarding hepatitis B are promoting early diagnosis and encouraging more people to get vaccinated and seek medical care. In the United States, the month of May is recognized as Hepatitis Awareness Month, and May 19th is designated as Hepatitis Testing Day. During this month, the national public health agency Centers for Disease Control and Prevention (CDC) in collaboration with its public health partners highlights the impact of this disease and raises awareness about viral hepatitis while emphasizing the need for testing and vaccination. Such campaigns also help to improve the understanding of viral hepatitis transmission, associated risk factors, and available treatment options, which is expected to elevate the market value.
North America Hepatitis B Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type:
The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Gilead Sciences, Inc.
This American biopharmaceutical received FDA approval for its drug Vemlidy® (tenofovir alafenamide) for the treatment of chronic hepatitis B virus infection in pediatric patients in 2022.
Merck & Co., Inc.
Merck & Co., Inc. is a leading science and technology company with a robust market presence. Its vaccine RECOMBIVAX HB is taken to prevent infection from all known subtypes of the hepatitis B virus.
GlaxoSmithKline plc (GSK)
This global provider of innovative vaccines and specialty medicines is actively engaged in strategic partnerships to develop pharmaceutical products. Its investigational antisense oligonucleotide is currently undergoing a phase III trial to assess its efficacy for the treatment of chronic hepatitis B.
Novartis AG
Novartis AG, a global healthcare company based in Switzerland, is committed to the development of treatment solutions for hepatitis B and C infections.
Other players in the market include Pfizer Inc., Sanofi, Johnson & Johnson, AbbVie Inc., Bristol Myers Squibb, and Dynavax Technologies.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
North America Hepatitis B Market Analysis
Hepatitis B is a vaccine-preventable liver infection that can result in a chronic infection leading to cirrhosis, liver cancer, and death. It is caused by the hepatitis B virus (HBV) and affects around 1.6 million people in the United States. The prevalence rate of the infection is higher in black, Hispanic, and Asian populations as compared to whites. Hepatitis B viral infection has the potential to progress to a chronic state and thus is a significant health challenge. Intensive research efforts are accelerating the development of innovative antiviral therapies and immune modulators, which is impacting the global hepatitis B market dynamics. Further, advancements in diagnostic technologies and improvements in healthcare infrastructure are some of the factors that contribute to the North America hepatitis B market growth.
The market is influenced by the presence of a supportive regulatory environment that expedites the introduction of novel treatment options. In February 2024, the global biopharma company GSK plc announced that its investigational antisense oligonucleotide (ASO) bepirovirsen has received Fast Track Designation from the US Food and Drug Administration to treat chronic hepatitis B. Developed jointly with California-based biotechnology company Ionis Pharmaceuticals, the designation request was made based on the positive results from phase IIb trials B-Clear and B-Sure. The company claims that Bepirovirsen (in combination with oral nucleoside/nucleotide analogues) is the only single agent in phase III development that demonstrated a clinically meaningful functional cure response in chronic hepatitis B patients. Such substantial investment in clinical studies by the leading pharmaceutical companies to develop effective medications for this viral infection is poised to boost the North America hepatitis B market demand in the forecast period.
Increased awareness initiatives and education campaigns regarding hepatitis B are promoting early diagnosis and encouraging more people to get vaccinated and seek medical care. In the United States, the month of May is recognized as Hepatitis Awareness Month, and May 19th is designated as Hepatitis Testing Day. During this month, the national public health agency Centers for Disease Control and Prevention (CDC) in collaboration with its public health partners highlights the impact of this disease and raises awareness about viral hepatitis while emphasizing the need for testing and vaccination. Such campaigns also help to improve the understanding of viral hepatitis transmission, associated risk factors, and available treatment options, which is expected to elevate the market value.
North America Hepatitis B Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type:
- Acute
- Chronic
- Immune Modulator Drugs
- Antiviral Drugs
- Hepatoprotectives
- Vaccine
- Surgery
- Oral
- Parenteral
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- United States of America
- Canada
The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Gilead Sciences, Inc.
This American biopharmaceutical received FDA approval for its drug Vemlidy® (tenofovir alafenamide) for the treatment of chronic hepatitis B virus infection in pediatric patients in 2022.
Merck & Co., Inc.
Merck & Co., Inc. is a leading science and technology company with a robust market presence. Its vaccine RECOMBIVAX HB is taken to prevent infection from all known subtypes of the hepatitis B virus.
GlaxoSmithKline plc (GSK)
This global provider of innovative vaccines and specialty medicines is actively engaged in strategic partnerships to develop pharmaceutical products. Its investigational antisense oligonucleotide is currently undergoing a phase III trial to assess its efficacy for the treatment of chronic hepatitis B.
Novartis AG
Novartis AG, a global healthcare company based in Switzerland, is committed to the development of treatment solutions for hepatitis B and C infections.
Other players in the market include Pfizer Inc., Sanofi, Johnson & Johnson, AbbVie Inc., Bristol Myers Squibb, and Dynavax Technologies.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 North America Hepatitis B Market Overview
- 3.1 North America Hepatitis B Market Historical Value (2018-2024)
- 3.2 North America Hepatitis B Market Forecast Value (2025-2034)
- 4 North America Hepatitis B Market Landscape*
- 4.1 North America Hepatitis B: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 North America Hepatitis B: Product Landscape
- 4.2.1 Analysis by Type
- 4.2.2 Analysis by Treatment
- 5 North America Hepatitis B Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 North America Hepatitis B Market Segmentation (218-2034)
- 6.1 North America Hepatitis B Market (2018-2034) by Type
- 6.1.1 Market Overview
- 6.1.2 Acute
- 6.1.3 Chronic
- 6.2 North America Hepatitis B Market (2018-2034) by Treatment
- 6.2.1 Market Overview
- 6.2.2 Immune Modulator Drugs
- 6.2.3 Antiviral Drugs
- 6.2.4 Hepatoprotectives
- 6.2.5 Vaccine
- 6.2.6 Surgery
- 6.3 North America Hepatitis B Market (2018-2034) by Route of Administration
- 6.3.1 Market Overview
- 6.3.2 Oral
- 6.3.3 Parenteral
- 6.3.4 Others
- 6.4 North America Hepatitis B Market (2018-2034) by Distribution Channel
- 6.4.1 Market Overview
- 6.4.2 Hospital Pharmacies
- 6.4.3 Retail Pharmacies
- 6.4.4 Online Pharmacies
- 6.5 North America Hepatitis B Market (2018-2034) by Country
- 6.5.1 Market Overview
- 6.5.2 United States of America
- 6.5.3 Canada
- 7 United States of America Hepatitis B Market (218-2034)
- 7.1 United States of America Hepatitis B Market (2018-2034) by Type
- 7.1.1 Market Overview
- 7.1.2 Acute
- 7.1.3 Chronic
- 7.2 United States of America Hepatitis B Market (2018-2034) by Treatment
- 7.2.1 Market Overview
- 7.2.2 Immune Modulator Drugs
- 7.2.3 Antiviral Drugs
- 7.2.4 Hepatoprotectives
- 7.2.5 Vaccine
- 7.2.6 Surgery
- 7.3 United States of America Hepatitis B Market (2018-2034) by Route of Administration
- 7.3.1 Market Overview
- 7.3.2 Oral
- 7.3.3 Parenteral
- 7.3.4 Others
- 7.4 Canada Hepatitis B Market (2018-2034) by Distribution Channel
- 7.4.1 Market Overview
- 7.4.2 Hospital Pharmacies
- 7.4.3 Retail Pharmacies
- 7.4.4 Online Pharmacies
- 8 Canada Hepatitis B Market (218-2034)
- 8.1 Canada Hepatitis B Market (2018-2034) by Type
- 8.1.1 Market Overview
- 8.1.2 Acute
- 8.1.3 Chronic
- 8.2 Canada Hepatitis B Market (2018-2034) by Treatment
- 8.2.1 Market Overview
- 8.2.2 Immune Modulator Drugs
- 8.2.3 Antiviral Drugs
- 8.2.4 Hepatoprotectives
- 8.2.5 Vaccine
- 8.2.6 Surgery
- 8.3 Canada Hepatitis B Market (2018-2034) by Route of Administration
- 8.3.1 Market Overview
- 8.3.2 Oral
- 8.3.3 Parenteral
- 8.3.4 Others
- 8.4 Canada Hepatitis B Market (2018-2034) by Distribution Channel
- 8.4.1 Market Overview
- 8.4.2 Hospital Pharmacies
- 8.4.3 Retail Pharmacies
- 8.4.4 Online Pharmacies
- 9 Regulatory Framework
- 10 Funding and Investment Analysis
- 10.1 Analysis by Funding Instances
- 10.2 Analysis by Type of Funding
- 10.3 Analysis by Funding Amount
- 10.4 Analysis by Leading Players
- 10.5 Analysis by Leading Investors
- 10.6 Analysis by Geography
- 11 Partnership and Collaborations Analysis
- 11.1 Analysis by Partnership Instances
- 11.2 Analysis by Type of Partnership
- 11.3 Analysis by Leading Players
- 11.4 Analysis by Geography
- 12 Supplier Landscape
- 12.1 Market Share by Top 5 Companies
- 12.2 Gilead Sciences, Inc.
- 12.2.1 Financial Analysis
- 12.2.2 Product Portfolio
- 12.2.3 Demographic Reach and Achievements
- 12.2.4 Mergers and Acquisitions
- 12.2.5 Certifications
- 12.3 Merck & Co., Inc.
- 12.3.1 Financial Analysis
- 12.3.2 Product Portfolio
- 12.3.3 Demographic Reach and Achievements
- 12.3.4 Mergers and Acquisitions
- 12.3.5 Certifications
- 12.4 GlaxoSmithKline plc (GSK)
- 12.4.1 Financial Analysis
- 12.4.2 Product Portfolio
- 12.4.3 Demographic Reach and Achievements
- 12.4.4 Mergers and Acquisitions
- 12.4.5 Certifications
- 12.5 Novartis AG
- 12.5.1 Financial Analysis
- 12.5.2 Product Portfolio
- 12.5.3 Demographic Reach and Achievements
- 12.5.4 Mergers and Acquisitions
- 12.5.5 Certifications
- 12.6 Pfizer Inc.
- 12.6.1 Financial Analysis
- 12.6.2 Product Portfolio
- 12.6.3 Demographic Reach and Achievements
- 12.6.4 Mergers and Acquisitions
- 12.6.5 Certifications
- 12.7 Sanofi
- 12.7.1 Financial Analysis
- 12.7.2 Product Portfolio
- 12.7.3 Demographic Reach and Achievements
- 12.7.4 Mergers and Acquisitions
- 12.7.5 Certifications
- 12.8 Johnson & Johnson
- 12.8.1 Financial Analysis
- 12.8.2 Product Portfolio
- 12.8.3 Demographic Reach and Achievements
- 12.8.4 Mergers and Acquisitions
- 12.8.5 Certifications
- 12.9 AbbVie Inc.
- 12.9.1 Financial Analysis
- 12.9.2 Product Portfolio
- 12.9.3 Demographic Reach and Achievements
- 12.9.4 Mergers and Acquisitions
- 12.9.5 Certifications
- 12.10 Bristol Myers Squibb
- 12.10.1 Financial Analysis
- 12.10.2 Product Portfolio
- 12.10.3 Demographic
- 12.10.4 Mergers and Acquisitions
- 12.10.5 Certifications
- 12.11 Dynavax Technologies
- 12.11.1 Financial Analysis
- 12.11.2 Product Portfolio
- 12.11.3 Demographic Reach and Achievements
- 12.11.4 Mergers and Acquisitions
- 12.11.5 Certifications
- 13 North America Hepatitis B Market – Distribution Model (Additional Insight)
- 13.1 Overview
- 13.2 Potential Distributors
- 13.3 Key Parameters for Distribution Partner Assessment
- 14 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 15 Company Competitiveness Analysis (Additional Insight)
- 15.1 Very Small Companies
- 15.2 Small Companies
- 15.3 Mid-Sized Companies
- 15.4 Large Companies
- 15.5 Very Large Companies
- 16 Payment Methods (Additional Insight)
- 16.1 Government Funded
- 16.2 Private Insurance
- 16.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
